Key facts
- Lupin's ranibizumab injection, Ranluspec™, has been approved by the U.S. FDA.
- Taipei Fertility Center's AI model improves normal embryo selection by up to 24%.
- Vcare PharmaTech's TRK inhibitor, Eratrectinib, has received marketing approval.
- Neurovia AI is named Official Government AI Cybersecurity Partner for a summit in Abu Dhabi on June 4, 2026.
- Primax Electronics corrected its news release regarding AI conference solutions, removing the term 'MDEP-ready development'.
- AVIA recognized nine health systems for digital innovation.
- Digital therapeutics showed a 0.54% HbA1c reduction at a summit in Shenzhen.
- Kexing Biopharm dosed the first subject in China for its Phase I trial of eye drug GB10.
- TBRx and BrainTap Sports are collaborating to enhance athletic performance and recovery.
- Epson launched new dvLED displays for the U.S. and Latin America.
Lupin Limited has achieved a significant milestone with the U.S. FDA's approval of its ranibizumab injection, Ranluspec™, for medical use. This marks a notable entry into the U.S. market for the global pharmaceutical company.
In the realm of reproductive health, TFC Taipei Fertility Center has introduced an artificial intelligence scoring system designed to enhance the selection of chromosomally normal embryos. This AI model aims to improve success rates for infertile couples who have experienced repeated implantation failure, with reported efficacy leading to a 24% increase in normal embryo identification.
Vcare PharmaTech's TRK inhibitor, Eratrectinib, has secured marketing approval. This drug is developed to target NTRK gene fusions, which are identified as key drivers in the development of various solid tumors.
Kexing Biopharm has commenced its Phase I clinical trial for GB10, an innovative ophthalmic drug developed by Shenzhen Kexing Pharmaceutical Co, Ltd. The first subject has been dosed in China, with the trial taking place in Shenzhen.
Robo.ai's subsidiary, Neurovia AI, has been appointed as an Official Government AI Cybersecurity Partner for The 3rd Government Cybersecurity Summit. This event is scheduled for June 4, 2026, in Abu Dhabi and underscores the increasing focus on cybersecurity for public agencies in the UAE. Neurovia AI's CTO is slated to present on trusted visual intelligence infrastructure.
Primax Electronics has issued a correction to a previous news release concerning its AI conference solutions. The company has removed the term "MDEP-ready development" from its descriptions. These solutions are designed to integrate with Qualcomm's edge AI platforms to facilitate intelligent meeting spaces.
AVIA has recognized nine leading health systems for their advancements in digital innovation, acknowledging their progress in areas such as utilization, AI maturity, and operational enhancements. This recognition was announced in conjunction with the Signal Over Noise Digital Transformation Summit.
At the 4th AGP & DTx Summit in Shenzhen, digital therapeutics were reported to demonstrate a 0.54% reduction in HbA1c levels. The summit, themed 'Beyond Glucose' and co-organized by SIBIONICS, highlighted a growing trend in diabetes care towards promoting active behavioral change.
TBRx and BrainTap Sports have announced a collaborative effort focused on improving athletic performance and recovery. Their joint initiative will utilize brain-focused methods, with TBRx founder Alex Guerrero and client Tom Brady noted as users of BrainTap technology.
Epson has expanded its commercial display portfolio by launching its first all-in-one dvLED displays for the U.S. and Latin American markets. The new LE-C1 Series utilizes COB technology to produce bright, high-contrast images, suitable for environments with significant ambient light.